Literature DB >> 28697564

An Intracellular Amyloid-β/AβPP Epitope Correlates with Neurodegeneration in those Neuronal Populations Early Involved in Alzheimer's Disease.

Gisela Esquerda-Canals1,2, Joaquim Martí-Clúa2, Alejandro R Roda1, Sandra Villegas1.   

Abstract

The main histopathological hallmarks of Alzheimer's disease (AD) are the extracellular deposition of neuritic amyloid plaques, composed of amyloid-β (Aβ) peptide, and the intracellular accumulation of neurofibrillary tangles, composed of hyperphosphorylated tau. Both traits are emulated in the 3xTg-AD mouse model. Because the relevance of this model in the bibliography and the main role of Aβ in neuronal impairment, here we have detailed the brain Aβ/AβPP distribution to subsequently quantify cellular density and intracellular burden for specific neuronal populations in the early stages of the disease. 6E10 immunoreactivity was evident in the deep layers of the cerebral cortex, in the pyramidal cell layer of the hippocampus, in the basolateral amygdala nucleus, and in the deep cerebellar nuclei macroneurons; whereas the specific neuronal populations with decreased cellular density were the large pyramidal neurons from the layers V-VI in the cerebral cortex, the pyramidal neurons from the CA2-3 region in the hippocampus, and the large neurons from the basolateral nucleus in the amygdala, apart from the already reported deep cerebellar nuclei. Interestingly, we found a strong correlation between intracellular Aβ/AβPP burden and cellular density in all these populations. In addition, behavioral testing showed the functional consequences of such a neuronal depletion. Concretely, anxious-like behavior is manifested in the corner and open-field tests, as well as cognitive functions shown to be impaired in the novel object recognition test and Morris water maze paradigm. To our knowledge, this is the first deep characterization of the specific neuronal populations affected in the 3xTg-AD mouse model.

Entities:  

Keywords:  3xTg-AD; 6E10 immunoreactivity; Alzheimer’s disease; AβPP; amyloid-β; behavioral alterations; neuronal loss

Mesh:

Substances:

Year:  2017        PMID: 28697564     DOI: 10.3233/JAD-170218

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  6 in total

Review 1.  Role of Intracellular Amyloid β as Pathway Modulator, Biomarker, and Therapy Target.

Authors:  Lucia Gallego Villarejo; Lisa Bachmann; David Marks; Maite Brachthäuser; Alexander Geidies; Thorsten Müller
Journal:  Int J Mol Sci       Date:  2022-04-22       Impact factor: 6.208

2.  Pharmacokinetic parameters and mechanism of action of an efficient anti-Aβ single chain antibody fragment.

Authors:  Gisela Esquerda-Canals; Joaquim Martí-Clúa; Sandra Villegas
Journal:  PLoS One       Date:  2019-05-31       Impact factor: 3.240

3.  Fas Apoptosis Inhibitory Molecule Blocks and Dissolves Pathological Amyloid-β Species.

Authors:  Hiroaki Kaku; Alexander V Ludlow; Michael F Gutknecht; Thomas L Rothstein
Journal:  Front Mol Neurosci       Date:  2021-12-14       Impact factor: 5.639

Review 4.  Amyloid-beta peptide and tau protein crosstalk in Alzheimer's disease.

Authors:  Alejandro R Roda; Gabriel Serra-Mir; Laia Montoliu-Gaya; Lidia Tiessler; Sandra Villegas
Journal:  Neural Regen Res       Date:  2022-08       Impact factor: 5.135

5.  Dihydroartemisinin Ameliorates Learning and Memory in Alzheimer's Disease Through Promoting Autophagosome-Lysosome Fusion and Autolysosomal Degradation for Aβ Clearance.

Authors:  Yueyang Zhao; Zhimin Long; Ya Ding; Tingting Jiang; Jiajun Liu; Yimin Li; Yuanjie Liu; Xuehua Peng; Kejian Wang; Min Feng; Guiqiong He
Journal:  Front Aging Neurosci       Date:  2020-03-02       Impact factor: 5.750

6.  Both Amyloid-β Peptide and Tau Protein Are Affected by an Anti-Amyloid-β Antibody Fragment in Elderly 3xTg-AD Mice.

Authors:  Alejandro R Roda; Laia Montoliu-Gaya; Gabriel Serra-Mir; Sandra Villegas
Journal:  Int J Mol Sci       Date:  2020-09-10       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.